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To investigate the effects of iron on GM-CSF production by
synovial fibroblasts, three different concentrations of ferric or
sodium citrate (0.01, 0.1, and 1 mmol/l at final concentration)
were added to synovial fibroblast 96 hour culture with three
different concentrations of IL1β (1, 10, and 100 ng/ml at final
concentration). Ferric citrate (1 mmol/l) but not sodium
citrate significantly enhanced GM-CSF production by synovial
fibroblasts on stimulation with 1 ng/ml of IL1β (fig 1A). Ferric
citrate (0.1 mmol/l) enhanced GM-CSF production by synovial
fibroblasts on stimulation with 10 ng/ml of IL1β (fig 1B). Also,
concentrations of 0.01 or 0.1 mmol/l ferric citrate enhanced
production of GM-CSF by synovial fibroblasts on stimulation
with 100 ng/ml of IL1β (fig 1C). However, ferric citrate at any
concentration tested did not enhance IL6 or IL8 production by
synovial fibroblasts on stimulation with any concentration of
IL1β including 100 ng/ml (data not shown).
To test whether iron regulates the transcriptional level of
GM-CSF production by synovial fibroblasts on stimulation
with IL1β, GM-CSF, IL6 and IL8 mRNA expression in synovial
fibroblasts were examined semiquantitatively by reverse
transcriptase-polymerase chain reaction (RT-PCR). The
method used for RT-PCR using specific primers for cytokines
and glyceraldehyde-3-phosphate dehydrogenase as a control
has been described in detail previously.5 The expression of
mRNA encoding these cytokines in synovial fibroblasts was
undetectable without IL1, and was dose dependent on IL1β
reaching a plateau after three hours in culture. Ferric citrate
(0.1 mmol/l) significantly enhanced IL1 induced GM-CSF
mRNA expression in synovial fibroblasts but not that of IL6 or
IL8 (data not shown).
GM-CSF is produced by T cells, macrophages, mast cells,
endothelial cells, and fibroblasts in response to specific activat-
ing signals. GM-CSF gene expression is controlled by binding
of transcription factors such as NF-GMa, NF-GMb, NF-κB,
Elf-1, NF-AT/AP1 complex, and Sp1 related complex to their
specific promoter regions.6 It is unknown which transcription
factors participate in the iron mediated regulation of IL1
induced GM-CSF production by synovial fibroblasts. Dlaska
and Weiss recently showed that iron regulates the transcription
of inducible nitric oxide synthase (iNOS) of macrophage-like
cells stimulated with interferon γ (IFNγ) and/or lipopolysac-
charide, and binding of NF-IL6 to its consensus motif within
the iNOS promoter was reduced by iron and enhanced by an
iron chelator.7 We found that iron enhanced IL1 induced
GM-CSF production by synovial fibroblasts. Taken together, the
intracellular iron levels might control GM-CSF production
induced by IL1 by mechanism(s) similar to the action of iron-
responsive element binding proteins on ferritin or transferrin
receptor synthesis or iNOS induction.8
We found that the effects of iron on GM-CSF production
induced by IL1 were different from those on IL6 or IL8
production. Agro et al reported that PGE2 enhanced IL6 and
IL8 but inhibited GM-CSF production by IL1 stimulated syno-
vial fibroblasts.9 Previously, we showed that iron decreased
PGE2 production by synovial fibroblasts.
3 Iron might enhance
GM-CSF production through down regulation of PGE2
production. Yoshida et al found that gold compounds and
divalent metal ions inhibited induction of IL6 and IL8 but not
production of GM-CSF by IL1 induced synovial fibroblasts
through inhibition of NF-κB binding to DNA.10 Thus, there
may be different signal transduction pathways among these
three cytokines in IL1 stimulated human synovial fibroblasts.
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Gouty attacks usually occur in patients with hyper-uricaemia, but patients with gout who have normouri-caemia are believed to be in the minority.1 2 This is a
common conception about gout because monosodium urate
crystals are formed at blood concentrations of uric acid over
420 µmol/l at a body temperature of 37°C.3 Recently, two
studies showed that the incidence of gouty attacks in
normouricaemia was as high as 39–43%,4 5 which is much
higher than our traditional view.1–3 However, few data on nor-
mouricaemia in gout have been reported so far.6–8 The preva-
lence of patients with gout who have normouricaemia at
diagnosis has not yet been determined, and even their clini-




We designed this study to determine the prevalence of
normouricaemia in patients with gout at diagnosis, and to
determine the natural course of normouricaemic gout and the
differences between the clinical characteristics of patients
with normouricaemic and hyperuricaemic gout at diagnosis.
We retrospectively reviewed 226 Korean patients who were
newly diagnosed as having gout at the Severance Hospital, Yon-
sei University College of Medicine, Seoul, Korea, between Janu-
ary 1996 and May 2000. The diagnosis of gout was made during
an acute attack of gouty arthritis and confirmed by either the
presence of negatively birefringent needle shaped crystals or by
satisfaction of the American College of Rheumatology criteria for
gout.9 Normouricaemia is defined as serum uric acid below 420
µmol/l in men and 360 µmol/l in women.10 Patients taking urate
lowering agents (allopurinol, probenecid) were excluded. Serum
uric acid was determined in samples drawn when a gouty attack
occurred at diagnosis by the uricase enzyme method.
Among the 226 gouty patients, 27 (12%) male patients
showed normouricaemia at diagnosis. Table 1 summarises the
clinical characteristics of the patients. Twenty one of 27
gouty patients with normouricaemia were followed up;
among these patients, 17 patients (81%) developed hyperuri-
caemia at a median of one month after diagnosis (range: one
week to 24 months) (fig 1), and only four patients (19%) still
showed normouricaemia. These four patients were followed
up at 11, 25, 28, and 34 months respectively, but showed no
more gouty attacks. All these patients had gout proved by the
presence of crystals and also had normouricaemia before
diagnosis.
The mean age at diagnosis was higher in gouty patients
with normouricaemia than in patients with hyperuricaemia,
whereas the duration from the first symptom to diagnosis, and
the prevalence of documented tophi, was higher in gouty
patients with hyperuricaemia. Serum uric acid, blood urea
nitrogen, and creatinine levels were lower in gouty patients
with normouricaemia (table 1).
We found that 27/226 (12%) of gouty patients at diagnosis had
normouricaemia, which was a lower incidence than found in the
two reports mentioned previously.4 5 The discrepancy between
our results and the results of those studies may be because the
previous studies analysed the incidence of gouty patients with
normouricaemia at the time of any acute attack,4 5 whereas we
analysed the incidence at the time of diagnosis.
Seventeen of 21 (81%) gouty patients with normouricaemia
at diagnosis subsequently became hyperuricaemic. The median
time for progression from normouricaemia to hyperuricaemia
was one month. Our results corresponded with those of
previous reports which showed that serum uric acid usually fell
during an acute attack and rose during the interim.4 5 Only four
gouty patients with normouricaemia at diagnosis continued to
have normouricaemia. This “genuine” normouricaemic gout
was present in only a small proportion, and these patients
followed a mild disease course without secondary attack.
These observations may help a doctor to decide whether a
diagnosis of gout can be made when normouricaemia is
present and may help in predicting the disease course of nor-
mouricaemic gout at diagnosis.
Table 1 Comparison of the clinical and laboratory variables of normouricaemic




gout (n=81)* p Value
Demographics
Age (years) 60.6 (13.9) 54.2 (11.8) 0.02
First symptom to diagnosis (months) 32.2 (36.3) 54.2 (66.3) 0.03
BMI (kg/m2) 23.8 (2.9) 23.1 (3.3) NS
Associated conditions
Hypertension 15 40 NS
Renal insufficiency† 5 28 NS
Heavy alcoholic intake 5 9 NS
Diabetes mellitus 2 11 NS
Precipitating events‡ 11 35 NS
Associated diseases§ 12 30 NS
Articular involvement
First MTP 19 57 NS
Upper extremities 1 15 NS
Lower extremities 27 76 NS
Polyarticular involvement¶ 11 45 NS
Documented tophi 4 36 0.006
Serum uric acid (µmol/l) 320 (80) 550 (90) <0.001
24 Hour urinary uric acid excretion (mmol/day) 4 (1) 4 (5) NS
BUN (mmol/l) 5.5 (2.0) 7.5 (1.5) 0.02
Creatinine (µmol/l) 100 (30) 140 (110) 0.002
BMI, body mass index; MTP, metatarsophalangeal joint; NS, not significant; BUN, blood urea nitrogen.
*Patients with hyperuricaemia were randomly selected from the study group using a table of random
sampling; †renal insufficiency was defined as a serum creatinine level above 130 µmol/l or a creatinine
clearance below 1.00 ml/s; ‡precipitating events for an acute attack of gout are binge drinking, meat,
surgery, infection, trauma, physical stress, and deterioration of underlying medical disease; §associated
diseases are acute renal failure, chronic renal failure, renal transplantation, coronary artery occlusion
disease, heart failure, stroke, and pulmonary tuberculosis; ¶polyarticular involvement was defined as more
than one joint affected in a gouty attack.
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HLA-DRB1*03 and DQB1*0302 associations in a subset
of patients severely affected with systemic lupus
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Genetic factors are likely to be important both in deter-mining the overall susceptibility to systemic lupus ery-thematosus (SLE) and in influencing the remarkable
clinical heterogeneity in disease expression found in affected
subjects. The more common clinical features seen in patients
with SLE include, skin and joint diseases, renal disease,
neuropsychiatric complications, and also some haematologi-
cal abnormalities. Genetic factors, together with environmen-
tal factors, strongly influence the development of SLE. Multi-
ple loci within the major histocompatibility complex (MHC)
have been implicated in susceptibility as have HLA class II
alleles, complement components, and tumour necrosis factor
(TNF) loci.
Currently it is believed that some HLA alleles are in genetic
linkage disequilibrium with certain disease related genes and
they regulate the immune responses. Since 1969, when the
first case of SLE was reported from India, the disease has been
extensively studied in different regions of the country—
namely, Chennai, Calcutta, Mumbai, and New Delhi. A statis-
tically significant clinical correlation comparing the clinical
variables from other racial groups of the world has been
reported in Indian patients with SLE.1 HLA association studies
from Indian patients with SLE are considerably limited2 and,
furthermore, varying interethnic differences in the associa-
tions have been reported from UK, South African and Icelan-
dic populations.3
PATIENTS AND METHODS
We studied 53 patients with severe SLE exhibiting the clinical
manifestations described by the 1982 revised American Rheu-
matism Association diagnostic criteria who had one or more
organ affected, such as kidney, brain, heart, and lungs. One
hundred and ten normal healthy subjects with the same eco-
nomic status and ethnic background comprised the controls
for this study over the same period. The autoantibody profiles
among the patients with SLE were studied by immunofluores-
cence and enzyme linked immunosorbent assay (ELISA).
HLA-A and B locus antigens were identified by a National
Institute of Health two stage microlymphocytotoxicity assay
using indigenous and commercial antisera. The HLA-DRB1
and HLA-DQB1 alleles were determined by a polymerase
chain reaction with sequence-specific primers technique from
the total genomic DNA extracted from the EDTA blood. The
phenotype frequencies, odds ratio, probability value, and con-
fidence intervals were estimated using our database and com-
puter programs. The p value was corrected by the Bonferoni
inequality method.
RESULTS AND DISCUSSION
A significant increase in the frequency of HLA-A1, A2, B27,
DRB1*03, DQB1*0302, and DQB1*0601 was found among
patients with SLE. HLA-A19, B15, DRB1*14(6), DRB1*1001,
and DQB1*0203 were found to be decreased in the patient
group compared with the controls (table 1). The high risk
alleles DRB1*03 and DQB1*0302 were then compared with
the findings for other populations of the world (table 2). The







(n=110) OR p Value CI
A1 39.60 17.80 2.99 <0.001 1.06to2.08
A2 45.30 29.70 1.95 <0.001 0.52to1.02
A19 26.50 43.40 0.48 <0.001 9.62to10.72
B15 2.00 16.30 0.16 <0.001 5.07to7.23
B27 12.20 2.30 5.40 <0.001 1.42to2.54
DRB1*
03 50.00 6.70 9.67 <0.0001 8.41to13.56
14(6) 12.50 40.00 0.25 <0.001 1.09to2.56
1001 6.30 30.00 0.21 <0.001 1.84to2.34
DQB1*
0302 56.30 10.00 8.02 <0.0001 12.88to
18.45
0203 12.50 50.00 0.17 <0.0001 1.32to2.56
%PF, percentage phenotype frequency; OR, odds ratio; CI, 95%
confidence interval.
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